Influenza A virus (IAV) is a worldwide public health problem causing 500,000 deaths each year. Palmitoyl-oleoyl-phophatidylglycerol (POPG) is a minor component of pulmonary surfactant, which has recently been reported to exert potent regulatory functions upon the innate immune system. In this report we demonstrate that POPG acts as a strong anti-viral agent against IAV. POPG markedly attenuated IL-8 production and cell death induced by IAV in 
INTRODUCTION
IAV is one of the most common viruses causing global health problems and life-threatening infections, resulting in an estimated 500,000 deaths each year (1) . In the US, 5-20% of the population is infected annually, producing 200,000 hospitalizations and 36,000 deaths (1-3).
Patients with chronic pulmonary disease (e.g. chronic obstructive pulmonary disease, asthma) are more susceptible to IAV infection and typically develop more severe symptoms requiring hospitalization, or ICU admissions (4) (5) (6) . In 2009-2010, the pandemic influenza A outbreak was caused by a novel IAV of swine origin and the H1N1 subtype. This pandemic spread rapidly and is illustrative of the problems of emergence of new strains (2, 7) . Vaccination is the standard strategy for prevention of influenza, but this effect varies and depends upon successful matching of the vaccine antigen with the epidemic, or pandemic virus, and population compliance with vaccination programs (1) . Vaccine shortages for rapidly spreading pandemic viruses can also limit population coverage and further intensify disease outbreaks and persistence.
Two classes of drugs currently available for treatments of influenza in non-immune individuals are the ion channel inhibitors (e.g. amantadine, remantadine), and the neuraminidase inhibitors (NAI) (e.g. Oseltamivir, Zanamivir, Peramivir) (1) . The near complete loss of efficacy of the ion channel inhibitors has led to heavy reliance upon NAIs (8) , which are currently standard drugs of choice for both prophylaxis and the early treatment of IAV infection. The frequency of NAI resistant IAV is approximately 1% in adults, and 4-8 % in children (9) . This resistance usually develops from prior application, or prophylaxis treatment with NAIs. However, the CDC recently reported that seasonal oseltamivir-resistant IAV has appeared independently of oseltamivir use. The osteltamvir-resistant IAV is a more frequent and serious problem in children (10) . The growing frequency of NAI-resistant IAV strains (9) (10) (11) highlights the importance of developing new agents for the treatment of influenza infection with novel mechanisms of action.
Pulmonary surfactant is a lipid and protein complex that regulates biophysical properties of the alveoli, and innate immune responses in the lung (12) . It is well recognized that the hydrophilic surfactant proteins (SP-A and SP-D) play multiple roles in regulating host defense. SP-A and SP-D bind to a variety of bacteria, fungi, and viruses with high affinity, and regulate the innate immune responses to these pathogens in the lung (12, 13) . Surfactant proteins are minor components of the surfactant complex accounting for approximately 10% of the material. The major constituents of pulmonary surfactant are phospholipids, with phosphatidylcholines (PC) as the dominant molecular class. Dipalmitoyl-PC is the most abundant lipid molecular species in surfactant and is the lipid most responsible for the reduction of surface tension at the air-tissue interface, within the alveolar compartment (13) . Phosphatidylglycerol (PG) is also present in surfactant and comprises approximately 10-mole % of the lipids. In humans, palmitoyl-oleoyl PG (POPG) is the most abundant molecular species present within the PG class (14) . The concentration of phospholipids in the extracellular pulmonary surfactant present in the alveolar hypophase, is estimated to be approximately 35 mg/ml (15) . These extraordinarily high extracellular phospholipid levels are not found in any other organ system. In addition, no other organ has such high levels of PG, although trace levels of PG are found in numerous organs where this lipid primarily functions at the subcellular level as a precursor to mitochondrial cardiolipin. The functions of such high levels of extracellular PG within the lung have been unclear, but recent studies now provide evidence that this lipid plays an important role in regulating innate immunity and viral infection (16) (17) (18) (19) (20) (21) . We recently reported that POPG, (17) (18) (19) . In addition to regulating cellular responses to LPS, CD14 has been implicated in the innate immune response to respiratory syncytial virus (RSV) (22) . This latter connection prompted recent examination of the effects of POPG upon RSV induced inflammation and infection (20) . These studies produced the unanticipated finding that POPG blocks RSV infection in vitro and in vivo by disrupting viral attachment to epithelial cell surfaces. An additional unanticipated finding was that supplemental POPG administered intranasally, markedly attenuated RSV infection in vivo, in mice (20) . This unexpected anti-viral activity of surfactant lipid led us to examine the effect of POPG as an IAV antagonist. The goals of this study were to determine if POPG could, 1) suppress the inflammatory response and cell death induced by IAV infection in epithelial cells in vitro, 2) inhibit viral attachment and subsequent replication in epithelial cells, 3) directly interact with IAV, and 4) attenuate IAV infection in vivo. Our findings demonstrate that supplemental POPG is a potent anti-viral agent against IAV. These findings strongly suggest that POPG and related compounds play an important role in pulmonary innate immunity and could be developed and used as a novel therapy against IAV infection.
MATERIAL AND METHODS

Viruses, tissue culture, infection and surfactant lipid treatments.
Influenza A viruses, Philippines 82/H3N2 and H1N1/PR8, were prepared as previously described (23) (24) (25) . Madin-Darby Canine Kidney (MDCK) cells and Beas2B cells were obtained 6 from ATCC (Manassas, Virginia, USA). Phospholipids were obtained from Avanti (Alabaster, AL, USA), and uni-lamellar liposomes were prepared as previously reported (16, 20) . To examine the effects of phospholipids on H3N2-IAV infection, cells were pretreated for 1h with POPG or POPC liposomes (20) .
Viral protein expression.
MDCK cells were grown in 24-wells plates, and pretreated for 1h with phospholipids prior to virus addition. Viruses were added to cells in the presence or absence of phospholipids, and the total well lysates were subjected to immunoblotting after 36hrs using Goat polyclonal anti IAV antibody (Millipore, Billerica, MA, USA) and β-actin (Cell Signaling Technology, USA).
Quantification of MP and NA protein expression was performed using NIH Image J1.34 software.
HA mRNA analysis by qRT-PCR.
MDCK cells were grown in 24-well plates, and H3N2-IAV adsorption was performed using a multiplicity of infection (MOI) of 0.5-1.0 for 2 hr at 37°C. Immediately following the adsorption, and at 24h, total well contents were processed for RNA extraction using a Qiagen RN-easy kit (Quagenm, Maryland, USA). HA mRNA expression was quantified using a qRT-PCR kit (Invitrogen, Camarillo, CA, USA).
Binding of Influenza A viruses to phopholipids and MDCK cells.
To examine the direct interactions between IAV and phospholipids, solid phase binding assays were performed (20) . Phospholipid coated wells were incubated for 2 hr at 37°C with varying 
In vivo suppression of Influenza A infection.
Female BALB/c mice at 6 weeks old, were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). Mice were anesthetized with 0.25g/kg avertin introduced intraperitoneally (20) .
Anesthetized mice were inoculated intranasally with a total volume of 50 µl of PBS in groups consisting of sham infection, IAV infection (80pfu/mouse), IAV infection plus POPG, and POPG alone. POPG liposomes were prepared in PBS (16, 20) , and mice were inoculated with 3 mg of the lipid premixed with the virus. On specific days, mice were euthanized by intraperitoneal injection of 0.25 ml of Nembutal (10 mg/ml). Bronchoalveolar lavage fluid (BALF) was used for differential cell quantification and IFN-γ analysis (20) . Homogenates of the left lungs were used for IAV plaque assays (26) . The right lungs were processed for lung histopathology score (20, 27) . Animal studies followed all prescribed guidelines and were approved by the Institutional Animal Care and Use Committee. 
RESULTS
POPG attenuates H3N2-IAV induced cytokine production in human bronchial epithelial
cells.
We first examined the effects of POPG upon IL-8 production induced by H3N2-IAV in a human bronchial epithelial cell line (BEAS2B). IL-8 is a typical early alarm cytokine released by tissues to recruit neutrophils to sites of injury and infection. Cells were pretreated with POPG, in the form of small unilamellar vesicles, for 1 hr, and challenged with H3N2-IAV at an MOI of 2/cell. As shown in Figure 1 Treatment of BEAS 2B cells with either POPG or POPC, in the absence of virus had no effect upon basal IL-8 production. From these experiments we conclude that POPG acts as a potent inhibitor of the inflammatory response elicited by H3N2-IAV in cultured human epithelial cells.
These results also indicate that the polar portion of POPG plays a major role in dictating the specificity of the lipid as an antagonist of H3N2-IAV induction of IL-8 production.
The concentrations of POPG used in these experiments are less than 10% of the PG levels found in pulmonary surfactant, suggesting that in vivo resident PG pools may provide significant protection from the virus. Previous studies have shown that the actions of POPG are not broadly pleiotropic for inhibition of IL-8 production, since the lipid does not suppress the expression of the cytokines induced by the TLR5 agonist, flagellin (20) . Additional control experiments demonstrate that POPG does not alter cellular protein synthesis, or growth. These findings clearly demonstrate that POPG can significantly suppress H3N2-IAV induced inflammatory cytokine production. To estimate phospholipid antagonism of virus propagation in MDCK cells, we examined the effects of POPG upon the expression of M1 Protein (MP) and neuraminidase (NA), which were measured following infection of the cells with H3N2-IAV for 36 hr. As shown in Figure 3A , at 2 hr after infection, using viral MOIs of either 0.5 or 1.0, neither MP, nor NA protein were detectable; but after 36hr infection, MP and NA protein expression clearly increased and was readily measurable. POPG treatment attenuated both MP and NA protein expression in a dose dependent manner with 1 mg/ml being significantly more effective than 200 µg/ml; ( Figure 3A , 3B). At 1mg/ml, POPG inhibited NA expression by 80% and MP expression by 75%. In contrast to POPG, POPC was completely ineffective. In addition to the H3N2 strain, we also performed experiments with the mouse adapted H1N1-PR8-IAV strain, because it is routinely used to Page 9 of 47 perform in vivo studies with mice. As shown in Figure S1 , infection of MDCK cells with H1N1-PR8-IAV at an MOI of 0.5, for 36hr, in the presence of 1 mg/ml POPG or POPC; produced results similar to that found for H3N2-IAV. The treatment with POPG at 1 mg/ml attenuated MP expression by 70% whereas POPC at 1 mg/ml did not alter MP expression. From these results, we conclude that POPG can suppress IAV protein expression from both H3N2-IAV and H1N1-PR8 strains, and the effect is dependent upon phospholipid structure. Quantitative analysis of the RT-PCR data in Figure 4B , showed that the inclusion of 200 µg/ml POPG during infection suppressed HA gene expression by 75%, and 1mg/ml POPG suppressed the expression by 88%. In contrast to the findings with POPG, the treatment with POPC was ineffective. These data demonstrate that POPG suppresses IAV HA mRNA expression in MDCK cells. Collectively, the experiments examining cytopathology, protein expression and mRNA expression demonstrate that POPG disrupts the IAV infection process at an early stage, and consequently prevents viral replication and cell death. These findings suggested that POPG might directly interact with the virus and interfere with cell binding, and additional experiments were conducted to test this idea.
POPG binds to influenza A virus with high affinity.
Page 10 of 47 11 To investigate the mechanism of the anti-viral effect of POPG, we examined the binding interaction between IAV and the lipid. Figure 5A shows the direct binding of H3N2-IAV to a POPG solid phase adsorbed to an ELISA plate. This binding interaction is virus concentration dependent, high affinity and saturable. In contrast to the virus binding to POPG, the binding to POPC has the characteristic of a low affinity, non-specific interaction. Figure 5B shows the results of similar experiments using H1N1-PR8 IAV with POPG, and also demonstrates high affinity, concentration dependent, and saturable binding. Compared with POPG, the lipid POPC is a weak-binding ligand for H1N1-PR8 IAV and the interaction is non-saturable and nonspecific.
Additional experiments examined whether POPG could interrupt binding of H3N2-IAV to cell surfaces. In these studies H3N2-IAV was adsorbed to MDCK cells at varying multiplicities of infection for 2 hr at 19°C (to block endocytosis), in either the absence, or presence of POPG. The data presented in Figure 5 provide compelling evidence that POPG directly binds to IAV and this interaction inhibits cell surface attachment of the virus. However, these findings do not provide any information about the consequences of POPG binding to IAV upon the integrity of the virus. In order to examine this issue in more detail and assess whether the lipid has direct virucidal activity, we conducted two types of experiments. In the first line of experimentation, H3N2-IAV (MOI of 1) was preadsorbed to MDCK cells in culture for 4hrs at 8C° (a temperature that inhibits all viral endocytosis), and then the adsorbed virus was exposed to POPG at either 200 µg/ml, or 1000 µg/ml, for an additional 4hr at 8C°. As a control phospholipid, POPC was added to separate MDCK monolayers also harboring preadsorbed virus. Following the incubation with lipid, the cultures were washed and warmed to 37C° to allow the viral infection to proceed. We reasoned that if the POPG acted as a virucidal agent to compromise the integrity of the virus, the lipid treatment should reduce the subsequent progress of the infection. As shown in Figure 6A , B and C, treatment of cell surface associated virus with POPG failed to disrupt cell infection, as monitored by the production of the viral proteins NA and MP, at 36hrs following the infection.
POPG antagonism of H3N2-IAV infection is reversible and dependent upon the timing of
A second approach to examining whether POPG was directly acting as a virucidal agent, tested the reversibility of the interaction of POPG with IAV. In these experiments H3N2-IAV (10 8 pfu/ml) was incubated with 1mg/ml POPG at 37C° for 1hr. Following the incubation, the virus and lipid were diluted 10 3 -fold in either the absence, or presence of 1 mg/ml POPG, and then used to infect monolayers of MDCK cells. As a control for these manipulations, identical aliquots of H3N2-IAV were incubated at 37C for 1hr in the complete absence of phospholipid. The infectivity of the IAV in these experiments was examined by quantifying fluorescent foci of viruses formed on the MDCK monolayers 6 hrs after infection, detected by antibody. The results presented in Figure 6D show that H3N2-IAV alone produced 1.01 ± 0.25 x 10 4 fluorescent foci per well, and virus transiently exposed to 1mg/ml lipid and then diluted 10 3 -fold produced 0.87 ± 0.23 x 10 4 foci per well, whereas virus exposed to a constant level of POPG produced 0.23 ± 0.04 x10 4 foci per well. These results demonstrate that the effects of POPG upon H3N2-IAV are reversible. Together, the data in panels 6A-D provide strong evidence that POPG is not directly
virucidal.
An additional conclusion from the data in panels 6A-C is that POPG must act prior to viral attachment to the cell surface, because virus already bound to cells is resistant to the antagonistic effects of the lipid. To further examine this latter conclusion, we applied a viral challenge to MDCK monolayers that were exposed to POPG for various periods before and after the addition of virus. To quantify the effects of viral infections in these experiments we measured cell viability at 36 hrs after adding viruses to the cultures. The results of these experiments are presented in Figure 6E . The viability of uninfected cells, 98.7 + 0.24%, and cells treated with POPG alone, 98.6 ± 0.3%, was equivalent. The addition of H3N2-IAV at an MOI of 0.5 reduced cell viability to 45.2 ± 6.8%. Pretreatment of MDCK cells with POPG followed by washout of the lipid prior to addition of virus, resulted in 44.7 ± 3.9% viability; whereas omission of the lipid washout resulted in 79.3 ± 1.7% viability. Simultaneous addition of lipid and virus provided significant protection to the monolayer and produced 70.8 ± 3.0% viability. The addition of lipid 1hr after infection showed marginal protection and yielded 57.1 ± 2.5% viability.
When the lipid was added at 2hrs after infection, there was no significant protection of the These in vitro properties of POPG suggested that the lipid might function as an effective antiviral agent in vivo, and further experiments were conducted to examine in vivo efficacy.
Intranasal administration of POPG suppresses IAV infection in mice.
We examined the potency of POPG as an anti IAV-agent using a mouse model of viral infection. increase in lymphocytic and neutrophilic cellular infiltrates in lavage by 60%. IFN-γ production was undetectable in lavage from control animals, and was 111.5 ± 24.7 pg/ml following virus infection. The POPG treatment suppressed the virally induced IFN-γ response by 81% ( Figure   7D ).
Lung tissue from experimental animals was examined and assigned a histopathology score (20) , and the data are shown in Figure 7E . H1N1-IAV infected animals had a 3-fold higher histopathology score than sham infected controls; and animals receiving virus plus POPG were not significantly different from sham-infected animals. Representative micrographs are shown in Figure 7E and reveal H1N1-IAV infection elicited a significant influx of inflammatory cells in alveolar and peribronchial areas, and pneumonia. POPG treatment markedly attenuated these virus-induced inflammatory changes, and the lipid treatment alone did not cause significant histological changes. From the data shown in Figures 6 and 7 , we conclude that POPG suppresses H1N1-PR8 IAV infection and viral replication in vivo, and markedly reduces the inflammatory responses to the virus. These findings strongly suggest that supplementary POPG could be an important and novel approach for prevention and treatment of IAV infections.
DISCUSSION
In this report we provide strong evidence that supplementary POPG, the major molecular The role of PG in pulmonary surfactant has long been enigmatic. Our recent work and earlier studies (16, (18) (19) (20) (21) provide strong evidence that PG plays an important role in suppressing TLRmediated inflammatory processes. We propose that the inhibitory actions of PG against TLRs, function to set a high threshold for the engagement of inflammatory cascades in the lung. Although the anti-viral properties of PG were not anticipated, it is clear that in vitro administration of this lipid, which is part of the intrinsic pulmonary surfactant system, can disrupt the infective processes of RSV and IAV, which are serious, problematic pathogens, worldwide. Most importantly, our data demonstrate that supplemental POPG introduced via the airways can significantly attenuate IAV infection in mice. This property of POPG suggests that the lipid has significant potential for preventing viral infections in at-risk human populations, and perhaps treating viral infections after they have become established.
STATISTICAL ANALYSIS
All results are shown as mean ± SE. ANOVA was used to determine the level of significant difference among all groups. Differences among groups were considered significant at P < 0.05. immunoblotting of cell extracts separated by gel electrophoresis using β-actin for standardization. Quantification of NA, MP and β-actin was performed using NIH Image J1-34 software.
In a second type of experiment we examined the reversal of POG antagonism of viral infection. Aliquots of IAV (1x10 8 pfu/ml) were incubated in either the absence or presence of 1mg/ml POPG for 1h at 37°C. Subsequently, the viral preparations were 
